U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Prostate Carcinoma

MedGen UID:
1710824
•Concept ID:
C5238404
•
Neoplastic Process

Definition

Prostate carcinoma that is resistant to treatment. [from NCI]

Professional guidelines

PubMed

Weekly administration of docetaxel and epirubicin as first-line treatment for hormone-refractory prostate carcinoma.
Neri B, Molinara E, Pantaleo P, Rangan S, Crisci A, Della Melina A, Raugei A, Villari D, Nicitat G
Oncol Res 2009;17(11-12):565-70. doi: 10.3727/096504009789745539. PMID: 19806787
Contemporary chemotherapeutic approaches for the treatment of hormone-refractory prostate carcinoma.
Walther PJ
World J Urol 2000 Jun;18(3):216-21. doi: 10.1007/s003450000126. PMID: 10926086
Treatment of hormone-refractory prostate carcinoma.
Fournier G
Eur Urol 1996;30 Suppl 1:32-7. doi: 10.1159/000474243. PMID: 8977988

Recent clinical studies

Etiology

Radiotherapy and concurrent metronomic chemotherapy in hormone-refractory prostate carcinoma: a Phase I study.
Morganti AG, Massaccesi M, Caravatta L, Macchia G, Picardi V, Deodato F, Ippolito E, Mignogna S, Ferro M, Cilla S, Mattiucci GC, Valentini V
Anticancer Res 2013 Oct;33(10):4585-9. PMID: 24123034
Targeting the endothelin axis in prostate carcinoma.
Pinto A, Merino M, Zamora P, Redondo A, Castelo B, Espinosa E
Tumour Biol 2012 Apr;33(2):421-6. Epub 2011 Dec 29 doi: 10.1007/s13277-011-0299-6. PMID: 22203496
Phase I/II study of weekly docetaxel and vinblastine in the treatment of metastatic hormone-refractory prostate carcinoma.
Tester W, Ackler J, Tijani L, Leighton J
Cancer J 2006 Jul-Aug;12(4):299-304. doi: 10.1097/00130404-200607000-00008. PMID: 16925974
Diethylstilboestrol versus bicalutamide in hormone refractory prostate carcinoma: a prospective randomized trial.
Manikandan R, Srirangam SJ, Pearson E, Brown SC, O'Reilly P, Collins GN
Urol Int 2005;75(3):217-21. doi: 10.1159/000087797. PMID: 16215308
Chemotherapy for patients with advanced prostate carcinoma: a new option for therapy.
Oh WK
Cancer 2000 Jun 15;88(12 Suppl):3015-21. doi: 10.1002/1097-0142(20000615)88:12+<3015::aid-cncr18>3.0.co;2-m. PMID: 10898346

Diagnosis

Study and detection of potential markers for predicting metastasis into lymph nodes in prostate cancer.
Papasotiriou I, Apostolou P, Ntanovasilis DA, Parsonidis P, Osmonov D, Jünemann KP
Biomark Med 2020 Oct;14(14):1317-1327. Epub 2020 Aug 17 doi: 10.2217/bmm-2020-0372. PMID: 32799659
Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480.
Ahles TA, Herndon JE 2nd, Small EJ, Vogelzang NJ, Kornblith AB, Ratain MJ, Stadler W, Palchak D, Marshall ME, Wilding G, Petrylak D, Holland JC; Cancer and Leukemia Group B
Cancer 2004 Nov 15;101(10):2202-8. doi: 10.1002/cncr.20655. PMID: 15484217
Cellular bases of the antitumor activity of a 7-substituted camptothecin in hormone-refractory human prostate carcinoma models.
Zuco V, Supino R, De Cesare M, Carenini N, Perego P, Gatti L, Pratesi G, Pisano C, Martinelli R, Bucci F, Zanier R, Carminati P, Zunino F
Biochem Pharmacol 2003 Apr 15;65(8):1281-94. doi: 10.1016/s0006-2952(03)00079-0. PMID: 12694869
Hormone therapy for patients with prostate carcinoma.
Klotz L
Cancer 2000 Jun 15;88(12 Suppl):3009-14. doi: 10.1002/1097-0142(20000615)88:12+<3009::aid-cncr17>3.3.co;2-5. PMID: 10898345
A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma: cancer and leukemia group B study 9181.
Dawson NA, Conaway M, Halabi S, Winer EP, Small EJ, Lake D, Vogelzang NJ
Cancer 2000 Feb 15;88(4):825-34. PMID: 10679652

Therapy

Radiotherapy and concurrent metronomic chemotherapy in hormone-refractory prostate carcinoma: a Phase I study.
Morganti AG, Massaccesi M, Caravatta L, Macchia G, Picardi V, Deodato F, Ippolito E, Mignogna S, Ferro M, Cilla S, Mattiucci GC, Valentini V
Anticancer Res 2013 Oct;33(10):4585-9. PMID: 24123034
Targeting the endothelin axis in prostate carcinoma.
Pinto A, Merino M, Zamora P, Redondo A, Castelo B, Espinosa E
Tumour Biol 2012 Apr;33(2):421-6. Epub 2011 Dec 29 doi: 10.1007/s13277-011-0299-6. PMID: 22203496
Natural and synthetic retinoids in prostate cancer.
Pasquali D, Rossi V, Bellastella G, Bellastella A, Sinisi AA
Curr Pharm Des 2006;12(15):1923-9. doi: 10.2174/138161206776873554. PMID: 16724957
Chemotherapy for patients with advanced prostate carcinoma: a new option for therapy.
Oh WK
Cancer 2000 Jun 15;88(12 Suppl):3015-21. doi: 10.1002/1097-0142(20000615)88:12+<3015::aid-cncr18>3.0.co;2-m. PMID: 10898346
Estramustine-based chemotherapy.
Hudes G
Semin Urol Oncol 1997 Feb;15(1):13-9. PMID: 9050135

Prognosis

Diethylstilboestrol versus bicalutamide in hormone refractory prostate carcinoma: a prospective randomized trial.
Manikandan R, Srirangam SJ, Pearson E, Brown SC, O'Reilly P, Collins GN
Urol Int 2005;75(3):217-21. doi: 10.1159/000087797. PMID: 16215308
Plasma osteopontin: associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma.
Hotte SJ, Winquist EW, Stitt L, Wilson SM, Chambers AF
Cancer 2002 Aug 1;95(3):506-12. doi: 10.1002/cncr.10709. PMID: 12209742
Weekly 1-hour infusion of paclitaxel. Clinical feasibility and efficacy in patients with hormone-refractory prostate carcinoma.
Trivedi C, Redman B, Flaherty LE, Kucuk O, Du W, Heilbrun LK, Hussain M
Cancer 2000 Jul 15;89(2):431-6. doi: 10.1002/1097-0142(20000715)89:2<431::aid-cncr31>3.0.co;2-b. PMID: 10918176
Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma: a phase II study.
Bracarda S, Tonato M, Rosi P, De Angelis V, Mearini E, Cesaroni S, Fornetti P, Porena M
Cancer 2000 Mar 15;88(6):1438-44. PMID: 10717628
Estramustine-based chemotherapy.
Hudes G
Semin Urol Oncol 1997 Feb;15(1):13-9. PMID: 9050135

Clinical prediction guides

Anti-tumor activity of non-nucleosidic reverse transcriptase inhibitors.
Landriscina M, Spadafora C, Cignarelli M, Barone C
Curr Pharm Des 2007;13(7):737-47. doi: 10.2174/138161207780249191. PMID: 17346188
Immunotherapy of patients with hormone-refractory prostate carcinoma pre-treated with interferon-gamma and vaccinated with autologous PSA-peptide loaded dendritic cells--a pilot study.
Hildenbrand B, Sauer B, Kalis O, Stoll C, Freudenberg MA, Niedermann G, Giesler JM, Jüttner E, Peters JH, Häring B, Leo R, Unger C, Azemar M
Prostate 2007 Apr 1;67(5):500-8. doi: 10.1002/pros.20539. PMID: 17262804
Phase I/II study of weekly docetaxel and vinblastine in the treatment of metastatic hormone-refractory prostate carcinoma.
Tester W, Ackler J, Tijani L, Leighton J
Cancer J 2006 Jul-Aug;12(4):299-304. doi: 10.1097/00130404-200607000-00008. PMID: 16925974
Chemotherapy for patients with advanced prostate carcinoma: a new option for therapy.
Oh WK
Cancer 2000 Jun 15;88(12 Suppl):3015-21. doi: 10.1002/1097-0142(20000615)88:12+<3015::aid-cncr18>3.0.co;2-m. PMID: 10898346
Estramustine-based chemotherapy.
Hudes G
Semin Urol Oncol 1997 Feb;15(1):13-9. PMID: 9050135

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...